Response to Comments: Mass Spectrometry (MS) Testing in Monoclonal Gammopathy (MG)

This document is a response to public and provider comments on the Mass Spectrometry (MS) Testing in Monoclonal Gammopathy LCD and does not itself specify clinical coverage criteria. It records that the official notice period began on 2022-06-16 and the final LCD determination became effective on 2022-08-01.

"This document is a response-to-comments for the Mass Spectrometry (MS) Testing in Monoclonal Gammopathy LCD; the official notice period for the final LCD began on 2022-06-16 and the final determina..."

Sign up to see full coverage criteria, indications, and limitations.